On February 3, 2026 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported leadership transitions for its next phase of innovation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Travis Thompson, who began at Bicycle in April 2018 and most recently served as Bicycle’s senior vice president and chief accounting officer and previously spent his career at EY in its life sciences practice supporting a broad range of companies of all sizes and stages of development, has been appointed as Bicycle’s chief financial officer (CFO). In this role, Mr. Thompson will continue to oversee finance and accounting functions, and now investor relations. Alethia Young, who has stepped down as CFO, will remain with Bicycle in an interim capacity for three months. Thereafter, Alethia will continue as a company advisor.
Michael Method, M.D., MPH, MBA, who began at Bicycle in June 2025 and most recently served as Bicycle’s senior vice president, clinical development, has been promoted to chief medical officer (CMO), overseeing all clinical development and the relationship with Bicycle’s Clinical Advisory Board. Dr. Method is an academic and clinical oncologist with extensive drug development experience at many oncology companies, including ImmunoGen and Eli Lilly. Eric Westin, M.D., who has retired from his role as CMO, will continue with Bicycle as a distinguished fellow.
Michael Skynner, who began at Bicycle in January 2016 and most recently served as Bicycle’s chief technology officer, will now serve as chief scientific officer. Dr. Skynner will oversee scientific discovery, early-stage pipeline development and the relationship with Bicycle’s Research and Innovation Advisory Board.
"Bicycle made significant progress in 2025 and looks forward to achieving its 2026 priorities. We believe our evolved leadership team, in collaboration with our expert board of directors and advisors, positions us to build momentum across our innovative pipeline and create shareholder value," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "On behalf of our board of directors and team, I want to thank Alethia and Eric for helping the company obtain a strong financial position and advance our clinical trials. As we look to the future, we are excited to progress our targeted oncology clinical programs that include our new radiopharmaceutical strategic partnerships. With strengthened operational capacity and financial runway expected into 2028, I am pleased to have Travis, Michael and Michael step into their new roles after successful tenures at Bicycle. Together, with the rest of our leadership team, talented employees and board of directors, we believe we can realize our goal to help patients live longer and live well."
(Press release, Bicycle Therapeutics, FEB 3, 2026, View Source [SID1234662425])